MoonLake Immunotherapeutics (MLTX)
| Market Cap | 1.31B -48.8% |
| Revenue (ttm) | n/a |
| Net Income | -257.08M |
| EPS | -3.87 |
| Shares Out | 72.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,212 |
| Open | 18.26 |
| Previous Close | 18.39 |
| Day's Range | 18.02 - 18.26 |
| 52-Week Range | 5.95 - 62.75 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 28.33 (+57.92%) |
| Earnings Date | May 11, 2026 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price target is $28.33, which is an increase of 57.92% from the latest price.
News
MoonLake price target raised to $45 from $40 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $45 from $40 and keeps a Buy rating on the shares. The company announced a positive outcome of…
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
Clear Street says MoonLake Immunotherapeutics’s (MLTX) positive pre-application meeting with the restores to its “prior strong positioning” in the hidradenitis suppurativa competitive landscape. The F...
MoonLake says aligned with FDA on submission plans for sonelokimab
MoonLake Immunotherapeutics (MLTX) announced a “positive” outcome of its final pre-BLA meeting held on April 1 with the FDA on the HS program of its Nanobody SLK. “During the meeting,…
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
MoonLake reported its financial results for the first quarter of 2026. As of March 31, 2026, MoonLake held cash, cash equivalents and short-term marketable debt securities of $357.9M. The company…
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
MoonLake Immunotherapeutics (MLTX) announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and ...
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammator...
MoonLake Immunotherapeutics management to meet with BTIG
Group Dinner Meeting with Management.in New York on March 31 hosted by BTIG.
MoonLake upgraded to Outperform from Underperform at Wolfe Research
Wolfe Research double upgraded MoonLake Immunotherapeutics (MLTX) to Outperform from Underperform with a price target of $24, up from $12. The firm says any “bearish commercial thesis” on MoonLake sha...
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Qize Ding upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a price target of $40, up from $12. The regulatory filing path for sonelokimab…
MoonLake price target raised to $70 from $45 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $70 from $45 and keeps a Buy rating on the shares. The firm has increased…
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $40 from $32 and keeps a Buy rating on the shares. The firm says the “favorable” axial spondyloarthritis…
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
Goldman Sachs raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $11 from $10 and keeps a Sell rating on the shares. MoonLake reported Q4 and full-year results, with…
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
Oppenheimer raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $35 from $30 and keeps an Outperform rating on the shares. MoonLake hosted a virtual Investor Day highlighting new…
MoonLake Immunotherapeutics Transcript: Investor Day 2026
Regulatory clarity enables BLA submission for SLK in HS with strong efficacy and safety data, while S-OLARIS and VELA programs show leading clinical outcomes and long-term benefits. Financial position supports ongoing development and commercial launch preparations.
MoonLake announces results from Phase 2 trial of Sonelokimab
MoonLake Immunotherapeutics (MLTX) announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic axSpA and announces its financial results for the...
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive compl...
MoonLake announces FDA granted Fast Track designation for sonelokimab
MoonLake Immunotherapeutics (MLTX) announces that the FDA has granted Fast Track designation for sonelokimab for the treatment of moderate-to-severe PPP. MoonLake had submitted a request for Fast Trac...
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
ZUG, Switzerland, February 2, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflam...
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
January 27, 2026 BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. III (Nasdaq: HLXC) (the “Company”) announced today that on January 26, 2026, it closed the initial public offering of...
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering
January 23, 2026 BOSTON, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. III (the “Company”) announced today that it priced its upsized initial public offering of 15,000,000 Class A ordinary...
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded MoonLake Immunotherapeutics (MLTX) to Sell from Neutral with a price target of $10, up from $8. While the firm believes sonelokimab’s outlook has improved slightly due to…
MoonLake price target raised to $32 from $26 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $32 from $26 and keeps a Buy rating on the shares. The company’s FDA Type B meeting outcome…
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a $24 price target The firm cites yesterday’s regulatory update for the upgrade. A Type B meeting with the FDA…
Unusually active option classes on open January 8th
Unusual total active option classes on open include: American Coastal Insurance Corp (ACIC), Regencell Bioscience Holdings Ltd (RGC), MoonLake Immunotherapeutics (MLTX), Kratos Defense (KTOS), Serve R...